Today’s Hottest: The Carlyle Group LP (NASDAQ:CG), Forrester Research (NASDAQ:FORR), Oramed Pharmaceuticals (NASDAQ:ORMP), BioPharmX Corporation (NYSEMKT:BPMX)

TriMas Corporation (NASDAQ:TRS) shares moved up 1.64% in last trading session and ended the day at $18.02. TRS Gross Margin is 27.30% and its has a return on assets of -2.40%. TriMas Corporation (NASDAQ:TRS) quarterly performance is -1.15%.

On April 13, 2016, TriMas Corporation (NASDAQ:TRS) entered into an Amended and Restated Agreement (the “Agreement”) with Glenn Welling, Engaged Capital, LLC and various affiliated entities (collectively, “Engaged”) to revise the terms of the Settlement Agreement dated as of February 24, 2015, by and among TriMas Corporation and Engaged Capital Master Feeder I, LP, Engaged Capital Master Feeder II, LP, Engaged Capital I, LP, Engaged Capital I Offshore, Ltd., Engaged Capital II, LP, Engaged Capital, LLC, Engaged Capital Holdings, LLC, Glenn Welling and Herbert Parker.

The Carlyle Group LP (NASDAQ:CG) ended the last trading day at $17.26. Company weekly volatility is calculated as 2.95% and price to cash ratio as 2.16. The Carlyle Group LP (NASDAQ:CG) showed a weekly performance of 7.74%.

Wholesale Trading Co-Op Insurance Services, a wholesale brokerage based in New York City, recently announced that its assets will be acquired by private-equity giant Carlyle Group. LP (NASDAQ:CG). Terms of the transaction were not disclosed.

On 15 April, Forrester Research Inc. (NASDAQ:FORR) shares advanced 0.70% and was closed at $34.43. FORR EPS growth in last 5 year was -5.80%. Forrester Research Inc. (NASDAQ:FORR) year to date (YTD) performance is 21.59%.

Forrester Research, Inc. (NASDAQ: FORR) will broadcast its first-quarter conference call at 4:30 p.m. Eastern time on Wednesday, April 27, 2016.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares moved up 6.29% in last trading session and ended the day at $9.30. ORMP has a return on assets of -28.60%. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) quarterly performance is 37.17%.

On 12 April, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced that the U.S. Patent and Trademark Office (PTO) has issued a Patent Term Adjustment (PTA) extending the patent term by 18 months for its patent No. 9,259,456, titled, “Methods and Compositions for Oral Administration of Proteins”. Oramed had previously announced receiving an allowance on the patent.

BioPharmX Corporation (NYSEMKT:BPMX) caters to the Healthcare space. Its weekly performance is -8.41%. On the last day of trading company shares ended up at $0.85. BioPharmX Corporation (NYSEMKT:BPMX) distance from 50-day simple moving average (SMA50) is -38.08%.

BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women’s health, announced that it will release its financial results for the fiscal fourth quarter and full year ended January 31, 2016 after the close of trading on Tuesday, April 26, 2016.